March 10, 2008 -- Tongjitang Chinese Medicines Company (NYSE: TCM) said that share-based compensation costs took its net operating income down to almost zero in the fourth quarter. Without special charges, which include share-based compensation and other public company-related charges, Tongjitang would have reported net operating income of 55.2 million RMB ($7.6 million), a 55% improvement over the 35.5 million RMB ($4.9 million) the company earned in Q4 of 2006. The disappointment came on the same day the company’s CEO announced a $10.20 per ADS offer for the company. More details...
